The company was seeking approval for an 8-milligram dose of its injection, Eylea, for patients with wet age-related macular degeneration — the leading cause of blindness among the elderly — and two other eye diseases that are common in people with diabetes.
Regeneron said the rejection was "solely due to an ongoing review of inspection findings at a third-party filler." The company did not provide further details on those findings or identify the third party, but said the decision was not related to the drug's efficacy, safety, trial design, labeling or drug substance manufacturing.But a delay won't help the company fight off threats to its Eylea drug franchise, which is facing competition fromRegeneron stock fell nearly 9% Tuesday after an FDA rejection of a higher-dose version of the company's blockbuster eye treatment.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: ABC - 🏆 471. / 51 Read more »
Dublin family celebrates FDA approval of gene therapy for Duchenne developed in Central Oh'It is huge. It’s going to change the course of this disease,' said Dublin mom Amber Nisley. 'I mean, it truly is a game changer. This has never happened before
Source: wsyx6 - 🏆 444. / 53 Read more »
AC Immune’s stock soars 13% after FDA grants fast-track designation to Alzheimer’s treatmentAC Immune SA’s stock soared 13% premarket Tuesday, after the Swiss-based biotech said it has received U.S. Food and Drug Administration fast-track...
Source: MarketWatch - 🏆 3. / 97 Read more »